Under-the-Skin Briumvi Supported by Early MS Clinical Trial Data

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients ...

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)

Under-the-skin Briumvi supported by early MS clinical trial data

A new formulation of Briumvi (ublituximab) — TG Therapeutics’ therapy for relapsing forms of multiple sclerosis (MS) — designed for possible at-home self-injection was generally well tolerated and showed biological activity consistent with the approved intravenous (into-the-vein) version, according to Phase 1 trial data. The Phase 1 trial is comparing the new subcutaneous, or under-the-skin, formulation of […] The post Under-the-skin Briumvi sup…

TG Therapeutics Boosts Growth With Strong Briumvi Trial

TG Therapeutics announced positive Phase 1 data for the subcutaneous version of Briumvi, a CD20 antibody for relapsing-remitting multiple sclerosis. The results not only met expectations but exceeded them in some areas. Bioavailability, safety, and tolerability were convincing and provide an important foundation for further program development. This brings a product closer that could nearly double the addressable market potential of Briumvi. At …